To Inhibition Effects Of Sorafenib Combined With Egcg On Human Hepatoma Cell Line HEBG2 And Effect Of Expression Of TNF-A And MMP-2

Purpose:Discuss on the inhibition effects of sorafenib combined epigallocatechin gallate on the proliferation of human hepatoma cell line HepG2 cell, as well as to explore the expression role of tumor necrosis factor-α (TNF-α) and matrix metalloproteinase-2(MMP-2).Methods:Logarithmic growth phase of human hepatoma cell line HepG2 cells were used for experiments. Experimental group was divided into single-drug sorafenib, EGCG monotherapy group and the combined group, which set up the blank group as the control group, the control group did not dosing medium. The control group was not added drug. After in-vitro cultrued, different concentrations of sorafenib, and the effect of EGCG in 24 hours on HepG2 cell proliferation were measured by MTT assay, and calculate the median inhibitory concentration. Then observe the inhibition rate after the combination of the two drugs. And detect the expression of TNF-a and MMP-2 within HepG2 cells by Westen bolt.Result:1.MTT assay results showed:Sorafenib and EGCG inhibited the proliferation of HepG2 cells, and the effect of the drug increased with concentration. The results showed that combination therapy significantly improved the inhibition rate, that can prove the existence of a synergistic effect. And calculated the half inhibitory concentration (IC50)of monotherapy group in 24 hours:sorafenib IC50=8.52±0.27 μmmol/L, EGCG IC50=59.39±1.43mg/L.2. Western blot results showed:sorafenib treatment group, the concentration was 8.5μmmol/L. EGCG treatment group, the concentration was 59.39mg/L, and combination administration group, TNF-α, MMP-2 expression decreased acted on Hepg2 cells after 24 hours. Synergistic combination group decreased more significantly, the difference was statistically significant (P<0.01). Conclusion:1.Sorafenib combined with EGCG can both inhibit HepG2 cell growth.2. Combined use of Sorafenib and EGCG both inhibited the inhibition rate than single druggroup was significantly decreased. The performance between both was synergistic effect.3. EGCG and sorafenib monotherapy group could cut TNF-α, MMP-2 expression of HepG2 cells, and inhibitory effect was significantly strengthened in combinition group.